Collagen Solutions PLC (LON:COS)

Collagen Solutions PLC (LON:COS)


Share Price
4.10 p
Change
-0.1 (-2.38 %)
Market Cap
£13.31 m
Proactive Investors - Run By Investors For Investors

Collagen Solutions PLC RNS Release

Hardman Research: Transition to sustainable growth


RNS Number : 9496L
Collagen Solutions PLC
25 July 2017
 

Hardman Research: Transitioning to sustainable growth

Transitioning to accelerated sustainable growth - Collagen Solutions is a biomaterials company developing and manufacturing medical grade collagen components for use in medical devices, research, and regenerative medicine. A number of investment initiatives have been introduced recently to accelerate the rate of growth, including global commercial infrastructure and development of a pipeline of finished medical devices, the first of which will be ChondroMimetic for repair of small cartilage lesions. Recent results have highlighted the progress that has been made, and 2018 looks set to benefit from the launch of its first proprietary finished device, ChondroMimetic.

Please click here for the full report:

http://hardmanandco.com/docs/default-source/company-docs/collagen-solutions-plc-documents/cos---2017-results---25-july-2017.pdf

 

To contact us:

Hardman & Co

35 New Broad Street

London

EC2M 1NH

www.hardmanandco.com

Follow us on Twitter @HardmanandCo

Contacts:

Dr Martin Hall

Dr Dorothea Hill

Dr Gregoire Pave

 

+44 20 7194 7622

 

[email protected]

[email protected]

[email protected]

About Hardman & Co: For the past 20 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge.  Our focus is to raise companies' profiles across the UK and abroad with outstanding research, investor engagement programmes and advisory services. Some of our notes have been commissioned by the company which is the subject of the note; this is clearly stated in the disclaimer where this is the case.

Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.

Our research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies.  It is not intended to be made available to unsophisticated retail investors. Anyone who is unsure of their categorisation should consult their professional advisors. This research is neither an offer, nor a solicitation, to buy or sell any security. Please read the note for the full disclaimer.


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRABIGDRXBDBGRS

Collagen Solutions PLC Timeline

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use